

**Name:** Amin

**Last name:** Talebi Bezmin Abadi

**Email:** Amin.talebi@modares.ac.ir; Amin.talebi@gmail.com

**Birthday:** 4<sup>th</sup> December 1983

**Birth Place:** Sari, Mazandaran Province, Iran

**B.S:** Biology, University of Golestan, Gorgan, Iran, 2005.

**M.S:** Medical Bacteriology, University of Tarbiat Modares, Tehran, Iran, 2009.

**PhD:** Medical Bacteriology, Utrecht University, Utrecht, the Netherlands, 2013.

### **Work interest:**

- Investigation of novel virulence factors of *Helicobacter pylori* in clinical isolates
- Treatment of *Helicobacter pylori*: new regimens and management of the infection

### **Reviewer in the journals:**

Helicobacter

Journal of Medical Microbiology

Japanese Journal of Infectious Diseases

Journal of Infection and Public Health

Govaresh

African Journal of Microbiology Research

Microbiology Research International

J Global Infectious Diseases

Annual Research & Review in Biology

Saudi Journal of Gastroenterology

### **Editorial board:**

Journal of Clinical Gastroenterology and Hepatology

### **Book chapters:**

1. *Helicobacter pylori*: A Worldwide Perspective 2014, Chapter (1). Publisher: Bentham Science Publishers, Oak Park, IL USA., Editor: Buzás György Miklós. **Main Bacteriological Features of *Helicobacter pylori***. Amin Talebi Bezmin Abadi, Johannes G. Kusters. Year: 2014; Pages 1-10; ISBN: 78-1-60805-738-2.
  
2. *Helicobacter pylori*: A Worldwide Perspective 2014, Chapter (10). Publisher: Bentham Science Publishers, Oak Park, IL USA., Editor: Buzás György Miklós. ***Helicobacter pylori* Infection in Iran: Epidemiology, Treatment and Diagnosis**. Amin Talebi Bezmin Abadi, Johannes G. Kusters. Year: 2014; Pages 216-233; ISBN: 978-1-60805-738-2.

### **Publications:**

1. **Talebi Bezmin Abadi A**, Lee Yeh Y. *Helicobacter pylori* vacA as marker for gastric cancer and gastroduodenal diseases: One but not the only factor. *Journal of Clinical Microbiology*. 2014. (In press).
  
2. **Talebi Bezmin Abadi A**, Lee Y. Inverse correlation between *Helicobacter pylori* and obesity—a conclusion too early? *Alimentary pharmacology & therapeutics*. 2014; 40(9):1119-1112.
  
3. **Talebi Bezmin Abadi A**, Mohabbati Mobarez A. High prevalence of *Helicobacter pylori* hopQ II genotype isolated from Iranian patients with gastroduodenal disorders. *Journal of pathogens*. 2014;2014.

4. **Talebi Bezmin Abadi A.** Type 2 diabetes and *Helicobacter pylori* infection: Starting point for the reality? *Indian Journal of Endocrinology and Metabolism*. 2014. (In press).
5. **Talebi Bezmin Abadi A.** *Helicobacter pylori*: Emergence of a Superbug. *Frontiers Medicine; Infectious Diseases*. 2014;1:34.
6. **Talebi Bezmin Abadi A.** *Helicobacter pylori*: A Beneficial Gastric Pathogen? *Frontiers Medicine; Gastroenterology*. 2014;1:26.
7. **Talebi Bezmin Abadi A.** The *Helicobacter pylori dupA*: A Novel Biomarker for Digestive Diseases. *Frontiers Medicine; Infectious Diseases*. 2014;1:13.
8. **Talebi Bezmin Abadi A.** Therapy of *Helicobacter pylori*: Present Medley and Future Prospective. *BioMed Research International*. 2014;2014:7.
9. **Talebi Bezmin Abadi A.** Novel idea: virulence-based therapy against *Helicobacter pylori* infection (smart therapy). *Frontiers Medicine; Gastroenterology*. 2014;1(18):1-2.
10. **Talebi Bezmin Abadi A**, et al. Virulent *Helicobacter pylori* in dental plaque and gastric specimen samples. *Journal of Clinical Gastroenterology and Hepatology*. 2014;1(1):1-4.
11. **Talebi Bezmin Abadi A**, et al. First case of *Helicobacter pylori* infection resistant to seven antibiotics in Iran. *Journal of the Brazilian Society of Tropical Medicine*. 2014;3.
12. **Talebi Bezmin Abadi A**, et al. Concomitant colonization of *Helicobacter pylori* in dental plaque and Gastric biopsy. *Journal of pathogen*. 2014.
13. **Talebi Bezmin Abadi A**, et al. Clinical relevance of the *cagA*, *tnpA* and *tnpB* genes in *Helicobacter pylori*. *BMC Gastroenterology*. 2014;14(3).
14. **Talebi Bezmin Abadi A**, Loffeld RJ, Constancia AC, Wagenaar JA, Kusters JG. Detection of the *Helicobacter pylori dupA* gene is strongly affected by the PCR design. *Journal of Microbiological Methods*. 2014;106:55-56.

15. **Talebi Bezmin Abadi A**, Taghvaei T. Virulence of *Helicobacter pylori*: Yesterday, today and tomorrow. *Medical Laboratory Journal*. 2014; 8(1):82-90.
16. **Talebi Bezmin Abadi A**. Virulence Factors of *Helicobacter pylori*: Practical biomarkers. *Recent Patents on Biomarkers*. 2014;4(3):4.
17. **Talebi Bezmin Abadi A**. *Helicobacter pylori* Infection in Iran: A new perspective. *Journal of Gastroenterology and Hepatology Research*. 2014;3(8).
18. **Talebi Bezmin Abadi A**. *Helicobacter pylori* Infection: Protective agent against *Mycobacterium tuberculosis*. *Journal of Clinical Gastroenterology and Hepatology*. 2014;1(2):1-2.
19. **Talebi Bezmin Abadi A**. Mix Infections of *Helicobacter pylori*: A major risk factor affecting genotyping studies. *International Journal of Bacteriology*. 2014;2014:1.
20. **Talebi Bezmin Abadi A**, Mobarez AM. Conclusive strategies for therapy and virotyping of *Helicobacter pylori*. *Saudi Journal of Gastroenterology*. 2014;20(5):325-326.
21. Ajami A, Shadman M, Rafiei A, Hosseini V, **Talebi Bezmin Abadi A**, Alizadeh A, et al. Prevalence of EPIYA motifs in *Helicobacter pylori* strains isolated from patients with gastroduodenal disorders in northern Iran. *Research in Molecular Medicine*. 2013;1(1):30-35.
22. **Talebi Bezmin Abadi A**, et al. Biomarker in *Helicobacter pylori* infection: the standoff condition? *Journal of the Brazilian Society of Tropical Medicine*. 2013;46(4):529-530.
23. **Talebi Bezmin Abadi A**, Taghvaei T, Mobarez AM, Vaira G, Vaira D. High correlation of *babA2*-positive strains of *Helicobacter pylori* with the presence of gastric cancer. *Internal and Emergency Medicine*. 2013;8(6):497-501.
24. **Talebi Bezmin Abadi A**, Ghasemzadeh A, Mobarez AM. Low frequency of *cagA*-positive *Helicobacter pylori* strains isolated from Iranian patients with MALT lymphoma. *Internal and Emergency Medicine*. 2013;8(1):49-53.

25. **Talebi Bezmin Abadi A**, Bonten MJ, Kusters JG. Comment to: "Different Antibiotic No Culture Eradication (DANCE) of *Helicobacter pylori*: An easy way to manage *H. pylori* eradication". *Digestive and Liver Disease*. 2013;45(5):438-439.
26. **Talebi Bezmin Abadi A**, Mobarez AM. *Helicobacter pylori* in the era of probiotics: A controversial application. *Saudi Journal of Gastroenterology*. 2013;19(5):240-241.
27. **Talebi Bezmin Abadi A**, Kusters JG. Association of inducible nitric oxide synthetase genotype and *Helicobacter pylori* infection gastric cancer risk may be due to faulty primer design. *World J Gastroenterol*. 2013;19(3):429-430.
28. Taghvaei T, **Talebi Bezmin Abadi A**, Ghasemzadeh A, Naderi BK, Mobarez AM. Prevalence of *horB* gene among the *Helicobacter pylori* strains isolated from dyspeptic patients: first report from Iran. *Internal and Emergency Medicine*. 2012;7(6):505-508.
29. **Talebi Bezmin Abadi A**, Johannes G, Kusters. Correct screening the virulence genes in *Helicobacter pylori*. *Gavarsh*. 2012;17(3):175-176.
30. **Talebi Bezmin Abadi A**, Taghvaei T, Wolfram L, Kusters JG. Infection with *Helicobacter pylori* strains lacking *dupA* is associated with an increased risk of gastric ulcer and gastric cancer development. *Journal of Medical Microbiology*. 2012;61(1):23-30.
31. **Talebi Bezmin Abadi A**, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of *Helicobacter pylori* to levofloxacin and moxifloxacin in Iran. *Internal and Emergency Medicine*. 2012;7(5):447-452.
32. **Talebi Bezmin Abadi A**, Taghvaei T, Wolfram L. Inefficiency of rapid urease test for confirmation of *Helicobacter pylori*. *Saudi Journal of Gastroenterology*. 2011;17(1):84-85.
33. **Talebi Bezmin Abadi A**, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in *Helicobacter pylori* strains isolated from the northern population of Iran. *Journal of Microbiology*. 2011;49(6):987-993.

34. **Talebi Bezmin Abadi A**, et al. *Helicobacter pylori homB*, but not *cagA*, is associated with gastric cancer in Iran. *Journal of Clinical Microbiology*. 2011;49(9):3191-3197.
35. **Talebi Bezmin Abadi A**, Taghvaei T, Ghasemzadeh A, Mobarez AM. High frequency of A2143G mutation in clarithromycin-resistant *Helicobacter pylori* isolates recovered from dyspeptic patients in Iran. *Saudi Journal of Gastroenterology*. 2011;17(6):396-399.
36. Tomatari H, Mobarez AM, Amini M, Hosseini D, **Talebi Bezmin Abadi A**. *Helicobacter pylori* resistance to metronidazole and clarithromycin in dyspeptic patients in Iran. *Iranian Red Crescent Medical Journal*. 2010;12(4):409-412.
37. **Talebi Bezmin Abadi A**, et al. An investigation of the prevalence of *iceA* genotypes in *Helicobacter pylori* strains isolated from peptic ulcer patients in Sari. *Arak Medical University Journal*. 2010;13(3):84-90.
38. **Talebi Bezmin Abadi A**, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of *Helicobacter pylori* in Mazandaran, North of Iran. *Helicobacter*. 2010;15(6):505-509.
39. **Talebi Bezmin Abadi A**, Taghvaei T, Vaira D. Considerable use of furazolidone in Iran. *Saudi Journal of Gastroenterology*. 2010;16(4):308-309.
40. **Talebi Bezmin Abadi A**, Mobarez A, Ajami A, Rafiee A, Taghwaii T. Evaluation on antibiotic resistance of *Helicobacter pylori* isolated from patients admitted to Tooba Medical Center, Sari. *Journal of Mazandaran University of Medical Sciences*. 2009;18(70). 26-32.